Published in Obesity and Diabetes Week, December 13th, 2004
CytRx Corp. (CytRx), a small-molecule drug-development and RNA interference (RNAi) technology company, is focused on creating a significant and sustainable product line to modify proteins responsible for ALS (amyotrophic lateral sclerosis), obesity, type 2 diabetes, HIV, and cytomegalovirus.
Steven Kriegsman, CytRx's president and CEO, stated, "In the third quarter of 2004, we were very pleased to have been able to reduce our losses from the previous quarter. We also negotiated the acquisition of the clinical and pharmaceutical assets of Biorex...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.